Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2013 (2013), Article ID 897434, 7 pages
http://dx.doi.org/10.1155/2013/897434
Research Article

Transplant Coordinators' Perceived Impact of Availability of Multiple Generic Immunosuppression Therapies on Patients, Workload, and Posttransplant Maintenance Therapy

1Division of Nephrology and Hypertension, Department of Internal Medicine, East Carolina University, Greenville, NC 27858, USA
2Department of Global Health Economics and Outcomes Research, Xcenda, LLC, Palm Harbor, FL 34685, USA
3Department of Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover NJ 07936, USA

Received 25 June 2012; Accepted 7 December 2012

Academic Editor: Gaetano Ciancio

Copyright © 2013 K. Parker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. W. Sollinger, “Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group,” Transplantation, vol. 60, no. 3, pp. 225–232, 1995. View at Google Scholar · View at Scopus
  2. G. L. Plosker and R. H. Foster, “Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation,” Drugs, vol. 59, no. 2, pp. 323–389, 2000. View at Google Scholar · View at Scopus
  3. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group, “KDIGO clinical practice guideline for the care of kidney transplant recipients,” American Journal of Transplantation, vol. 9, supplement 3, pp. S1–S155, 2009. View at Publisher · View at Google Scholar
  4. T. van Gelder and ESOT Advisory Committee on Generic Substitution, “European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs,” Transplant International, vol. 24, no. 12, pp. 1135–1141, 2011. View at Publisher · View at Google Scholar
  5. Food and Drug Administration, “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations,” 2011, http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm.
  6. R. R. Alloway, R. Isaacs, K. Lake et al., “Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants,” American Journal of Transplantation, vol. 3, no. 10, pp. 1211–1215, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. J. D. Momper, T. A. Ridenour, K. S. Schonder, R. Shapiro, A. Humar, and R. Venkataramanan, “The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function,” American Journal of Transplantation, vol. 11, no. 9, pp. 1861–1867. View at Publisher · View at Google Scholar
  8. H. Müller, S. Solari, C. Zuñiga et al., “Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile,” Transplantation Proceedings, vol. 40, no. 3, pp. 705–707, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Videla and C. Godoy, “Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome,” Transplantation Proceedings, vol. 39, no. 3, pp. 602–605, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Bulsara, A. McKenzie, F. Sanfilippo, C. D. J. Holman, and J. E. Emery, “Not the full Monty: a qualitative study of seniors perceptions of generic medicines in Western Australia,” Australian Journal of Primary Health, vol. 16, no. 3, pp. 240–245, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. N. Al Ameri, C. Whittaker, A. Tucker, M. Yaqoob, and A. Johnston, “A survey to determine the views of renal transplant patients on generic substitution in the UK,” Transplant International, vol. 24, no. 8, pp. 770–779, 2011. View at Publisher · View at Google Scholar
  12. A. S. Kesselheim, A. S. Misono, J. L. Lee et al., “Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis,” Journal of the American Medical Association, vol. 300, no. 21, pp. 2514–2526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. B. L. Strom, “Generic drug substitution revisited,” The New England Journal of Medicine, vol. 316, no. 23, pp. 1456–1462, 1987. View at Google Scholar · View at Scopus
  14. H. Håkonsen, M. Eilertsen, H. Borge, and E. L. Toverud, “Generic substitution: additional challenge for adherence in hypertensive patients?” Current Medical Research and Opinion, vol. 25, no. 10, pp. 15–21, 2009. View at Publisher · View at Google Scholar
  15. G. B. Klintmalm, “Immunosuppression, generic drugs and the FDA,” American Journal of Transplantation, vol. 11, no. 9, pp. 1765–1766, 2011. View at Publisher · View at Google Scholar
  16. E. Tichy and R. Alloway, “Generic Immunosuppressants Webcast,” American Society of Transplantation, June 2011, http://www.a-s-t.org/podcasts/generic-immunosuppressants.
  17. M. A. Chisholm, “Enhancing transplant patients' adherence to medication therapy,” Clinical Transplantation, vol. 16, no. 1, pp. 30–38, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. D. R. J. Kuypers, Y. Le Meur, M. Cantarovich et al., “Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 2, pp. 341–358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Ciancio, G. W. Burke, D. Roth, and J. Miller, “Tacrolimus and mycophenolate mofetil regimens in transplantation: benefits and pitfalls,” BioDrugs, vol. 11, no. 6, pp. 395–407, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. R. E. S. Bullingham, A. J. Nicholls, and B. R. Kamm, “Clinical pharmacokinetics of mycophenolate mofetil,” Clinical Pharmacokinetics, vol. 34, no. 6, pp. 429–455, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. C. R. Ensor, J. Trofe-Clark, S. Gabardi, L. M. McDevitt-Potter, and M. A. Shullo, “Generic maintenance immunosuppression in solid organ transplant recipients,” Pharmacotherapy, vol. 31, no. 11, pp. 1111–1129, 2011. View at Publisher · View at Google Scholar
  22. D. J. Cohen and B. Murphy, “Drug coverage for transplantation turns into political football: big business trumps patients,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 5, pp. 746–747, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. E. Ehlers, “Financial aspects of organ transplantation,” Nephrology Nursing Journal, vol. 29, no. 3, pp. 285–291, 2002. View at Google Scholar · View at Scopus
  24. B. Marshall and J. P. Swearingen, “Complexities in transplant revenue management,” Progress in Transplantation, vol. 17, no. 2, pp. 94–98, 2007. View at Google Scholar · View at Scopus
  25. M. Masri, “The generics in transplantation and the rules on their use,” Experimental and Clinical Transplantation, vol. 1, no. 1, pp. 65–68, 2003. View at Google Scholar · View at Scopus